FI106466B - Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi Download PDF

Info

Publication number
FI106466B
FI106466B FI932997A FI932997A FI106466B FI 106466 B FI106466 B FI 106466B FI 932997 A FI932997 A FI 932997A FI 932997 A FI932997 A FI 932997A FI 106466 B FI106466 B FI 106466B
Authority
FI
Finland
Prior art keywords
benzyloxy
difluoro
amino
phenyl
ethyl acetate
Prior art date
Application number
FI932997A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932997A (fi
FI932997A0 (fi
Inventor
Daniel Schirlin
Celine Tarnus
Dorsselaer Viviane Van
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI932997A publication Critical patent/FI932997A/fi
Publication of FI932997A0 publication Critical patent/FI932997A0/fi
Application granted granted Critical
Publication of FI106466B publication Critical patent/FI106466B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
FI932997A 1991-01-02 1993-06-29 Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi FI106466B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP91400005 1991-01-02
EP91400005 1991-01-02
US9109741 1991-12-20
PCT/US1991/009741 WO1992012123A1 (en) 1991-01-02 1991-12-20 Anti-viral compounds
US78809897 1997-01-23
US08/788,098 US5716973A (en) 1991-01-02 1997-01-23 Anti-viral compounds

Publications (3)

Publication Number Publication Date
FI932997A FI932997A (fi) 1993-06-29
FI932997A0 FI932997A0 (fi) 1993-06-29
FI106466B true FI106466B (fi) 2001-02-15

Family

ID=26129945

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932997A FI106466B (fi) 1991-01-02 1993-06-29 Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi

Country Status (19)

Country Link
US (1) US5716973A (ja)
EP (1) EP0565631B1 (ja)
JP (1) JP3198416B2 (ja)
AT (1) ATE143025T1 (ja)
AU (1) AU649766B2 (ja)
CA (1) CA2098020C (ja)
DE (1) DE69122266T2 (ja)
DK (1) DK0565631T3 (ja)
ES (1) ES2094344T3 (ja)
FI (1) FI106466B (ja)
GR (1) GR3021988T3 (ja)
HU (1) HU210647B (ja)
IE (1) IE75381B1 (ja)
IL (1) IL100477A (ja)
NO (1) NO180334C (ja)
NZ (1) NZ241099A (ja)
PT (1) PT99961B (ja)
WO (1) WO1992012123A1 (ja)
ZA (1) ZA9110141B (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2126794C1 (ru) * 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
GB9303518D0 (en) * 1993-02-22 1993-04-07 Merrell Dow Pharma Combinations of retroviral inhibitors
EP0707564B1 (en) * 1993-07-08 2000-09-20 Merrell Pharmaceuticals Inc. Difluoro statone analogs
DE69418050T2 (de) * 1993-09-09 1999-11-25 Merrell Pharma Inc Antivirale analoge von difluorostaton
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
JP3574455B2 (ja) * 1994-02-04 2004-10-06 メレルファーマスーティカルズ インコーポレイテッド 抗ウイルス剤として有用なマクロ環式ジフルオロスタトン誘導体類
HUT76648A (en) * 1994-07-15 1997-10-28 Merrell Pharma Inc Difluorostatone, pharmaceutical compositions containing them and process for producing them
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171103A (en) * 1966-03-24 1969-11-19 Gas Council Hydrogenation of Hydrocarbons.
US5066643A (en) * 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
CH672792A5 (ja) * 1985-02-19 1989-12-29 Sandoz Ag
DE3674131D1 (de) * 1985-04-19 1990-10-18 Upjohn Co Substituierte dihalo-statin-reninhemmungsmittel.
GB8619182D0 (en) * 1986-08-06 1986-09-17 Sandoz Ltd Peptides & derivatives
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
FR2614533A1 (fr) * 1987-04-23 1988-11-04 Sandoz Sa Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
GB2212158A (en) * 1987-12-15 1989-07-19 Sandoz Ltd Trialkylsilymethyl-substituted peptides; renin inhibitors
IL90872A0 (en) * 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
WO1990000399A1 (en) * 1988-07-08 1990-01-25 Smithkline Beckman Corporation Retroviral protease binding peptides
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
KR100220876B1 (ko) * 1991-01-02 1999-10-01 슈테펜엘.네스비트 항 바이러스 화합물
CZ229594A3 (en) * 1992-03-25 1995-04-12 Pfizer Peptides, process of their preparation, their use and pharmaceutical compositions based thereon
EP0957093A3 (en) * 1992-05-21 2000-04-12 Monsanto Company Retrovial protease inhibitors

Also Published As

Publication number Publication date
GR3021988T3 (en) 1997-03-31
AU649766B2 (en) 1994-06-02
DE69122266T2 (de) 1997-03-27
NZ241099A (en) 1994-08-26
IE914580A1 (en) 1992-07-15
FI932997A (fi) 1993-06-29
JPH07502255A (ja) 1995-03-09
NO180334C (no) 1997-04-02
ES2094344T3 (es) 1997-01-16
HUT65739A (en) 1994-07-28
HU210647B (en) 1995-06-28
EP0565631A1 (en) 1993-10-20
ATE143025T1 (de) 1996-10-15
WO1992012123A1 (en) 1992-07-23
NO932377D0 (no) 1993-06-29
NO180334B (no) 1996-12-23
ZA9110141B (en) 1992-10-28
AU9179091A (en) 1992-08-17
NO932377L (no) 1993-06-29
HU9301918D0 (en) 1993-12-28
JP3198416B2 (ja) 2001-08-13
CA2098020A1 (en) 1992-07-03
CA2098020C (en) 2003-10-21
IE75381B1 (en) 1997-09-10
DE69122266D1 (de) 1996-10-24
EP0565631B1 (en) 1996-09-18
IL100477A (en) 1996-07-23
PT99961B (pt) 1999-06-30
PT99961A (pt) 1993-01-29
FI932997A0 (fi) 1993-06-29
US5716973A (en) 1998-02-10
DK0565631T3 (da) 1996-10-07

Similar Documents

Publication Publication Date Title
FI106466B (fi) Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi
EP0337714A3 (en) Hiv protease inhibitors useful for the treatment of aids
JPH0741497A (ja) レトロ等立体性ジペプチド、その製造方法及び薬剤におけるレニン阻害剤としてのその使用
AU672867B2 (en) 4-amino-3-hydroxycarboxylic acid and their use as anitvirals
US5559140A (en) Difluoro statone analogs
FI120389B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi
AU683927B2 (en) Difluoro statone antiviral analogs
KR100367379B1 (ko) 항바이러스제로유용한마크로시클릭디플루오로스타톤유도체
US6114380A (en) Difluoro statone analogs

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS INC.

Free format text: AVENTIS INC.